2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Art. -Nr. Produktname CAS. Nr. Reinheit Chemische Struktur
  • HY-W020576
    Rivastigmine metabolite 139306-10-8 99.01%
    Rivastigmine metabolite (NAP 226-90) is a metabolite produced by the hydrolysis of Rivastigmine (HY-17368). Rivastigmine metabolite serves as a surrogate marker to track the bioavailability, metabolic extent, and transdermal patch delivery rate of Rivastigmine.
    Rivastigmine metabolite
  • HY-W026109
    FTO-IN-12 955328-22-0 98%
    FTO-IN-12 (Compound 2) is an inhibitor of fat mass and obesity-related protein (FTO). Kd and IC50 values are 185 nM and 1.46 μM, respectively. FTO-IN-12 can be used in the study of neurodegenerative diseases.
    FTO-IN-12
  • HY-W028389
    Pyrazolam 39243-02-2 98%
    Pyrazolam is a brominated triazolo benzodiazepine psychoactive substance with oral effectiveness. Pyrazolam produces anxiolytic, sedative, and sleep-promoting effects. Pyrazolam can be used for the research of anxiety.
    Pyrazolam
  • HY-W029659
    1-Benzyl-1,2,3,4-tetrahydro-isoquinoline 19716-56-4 98%
    1-Benzyl-1,2,3,4-tetrahydro-isoquinoline is an endogenous metabolite present in Cerebrospinal_Fluid that can be used for the research of Parkinson's Disease.
    1-Benzyl-1,2,3,4-tetrahydro-isoquinoline
  • HY-W031620
    VGSCs-IN-1 1204296-79-6 99.92%
    VGSCs-IN-1 (compound 14), a 2-piperazine analog of Riluzole (HY-B0211), is a human voltage-gated sodium channels (VGSCs) inhibitor. VGSCs-IN-1 shows great Nav1.4 blocking activity. VGSCs-IN-1 has a pKa of 7.6 and a cLog P of 2.4. VGSCs-IN-1 can be used for cell excitability disorders research.
    VGSCs-IN-1
  • HY-W032938
    COX-1-IN-4 37928-17-9 98%
    COX-1-IN-4 (Compound P10) is a selective COX-1 inhibitor (IC50s: COX-1 = 0.09 μM; COX-2 = 2.49 μM). COX-1-IN-4 reduces the production of NO as well as the expression of the iNOS protein. COX-1-IN-4 can be used in the research of neuroinflammation.
    COX-1-IN-4
  • HY-W035384
    MAO-B ligand-1 1010879-39-6 98%
    MAO-B ligand-1 is a MAO-B inhibitor, with IC50 values of 22.57 and 3.83 nM for hMAO-A and hMAO-B, respectively.
    MAO-B ligand-1
  • HY-W035404
    1-(1,3-Diphenylpropan-2-yl)pyrrolidine hydrochloride 102009-66-5 98%
    1-(1,3-Diphenylpropan-2-yl)pyrrolidine hydrochloride is structurally similar to known dissociative anesthetics.
    1-(1,3-Diphenylpropan-2-yl)pyrrolidine hydrochloride
  • HY-W040171
    Tefluthrin 79538-32-2 98%
    Tefluthrin is a pyrethroid insecticide. Tefluthrin prolongs the opening time of Nav1.6 sodium channels, leading to membrane depolarization and conductance block in the insect nervous system, thereby disrupting neural function.
    Tefluthrin
  • HY-W040176
    N-PTyrosine PA ammonium 799268-45-4 98%
    N-PTyrosine PA (N-Palmitoyl-tyrosine phosphoric acid) ammonium is a lysophosphatidic acid (LPA) receptor modulator, which exhibits weak inhibitory activity against LPA1 and partial agonist properties towards LPA5. N-PTyrosine PA ammonium inhibits the activation of LPA receptors and downstream responses by competing with agonists for binding sites. N-PTyrosine PA ammonium can induce morphological changes and aggregation, and also inhibit LPA-induced morphological changes through receptor desensitization caused by pre-incubation. N-PTyrosine PA ammonium can be used in the research of related diseases such as atherosclerosis and acute ischemic syndromes (e.g., unstable angina, myocardial infarction, stroke).
    N-PTyrosine PA ammonium
  • HY-W040555
    Norquetiapine dihydrochloride 111974-74-4 99.91%
    Norquetiapine ( N-Desalkylauetiapine) dihydrochloride, a metabolite of Quetiapine (HY-14544), is a selective HCN1 channel inhibitor, with an IC50 of 13.9 μM. Norquetiapine dihydrochloride selectively inhibits noradrenaline reuptake, is a partial 5-HT1A (Ki = 45 nM) receptor agonist, and acts as an antagonist at presynapticα2 (Ki = 237 nM), 5-HT2C(Ki = 107 nM), and 5-HT7 (Ki = 76 nM) receptors. Norquetiapine dihydrochloride blocks the human cardiac sodium channel Nav1.5 in a state-dependent manner. Norquetiapine dihydrochloride shows partial anti-inflammatory effects in LPS (HY-D1056) injected C57BL/6 mice. Norquetiapine dihydrochloride can be used for the study of depression and inflammation.
    Norquetiapine dihydrochloride
  • HY-W049335
    6,9-Dichloro-1,2,3,4-tetrahydroacridine 5396-25-8 98%
    6,9-Dichloro-1,2,3,4-tetrahydroacridine (compound 26) is an intermediate for the synthesis of acetylcholinesterase (AChE) inhibitors, which can be used in the study of Alzheimer's disease.
    6,9-Dichloro-1,2,3,4-tetrahydroacridine
  • HY-W052248
    RU 23686 free base 52157-82-1 98%
    RU 23686 free base is a piperidinylindole derivative. RU 23686 free base can be used to investigate the extent to which different neurotransmitters by the interaction with pharmacological agents.
    RU 23686 free base
  • HY-W053641
    (E)-2-Nitrocinnamic acid 1013-96-3
    (E)-2-Nitrocinnamic acid (Compound 1k) is an Acetylcholinesterase inhibitor. (E)-2-Nitrocinnamic acid is applicable to research related to Alzheimer's disease.
    (E)-2-Nitrocinnamic acid
  • HY-W061043
    DOV-216,303 86215-36-3 98%
    DOV-216,303 is an antidepressant compound. DOV-216,303 inhibits the reuptake of norepinephrine (NE), serotonin (5‐HT), and dopamine (DA), with IC50 values of 14 nM, 20 nM and 78 nM for hSERT, hNET and hDAT, respectively. DOV-216,303 increases monoamine release in the prefrontal cortex of olfactory bulbectomized (OBX) rats.
    DOV-216,303
  • HY-W070739
    GABAA receptor modulator-12 6252-98-8 98%
    GABAA receptor modulator-12 (Compound 5) is a GABAA receptor modulator. GABAA receptor modulator-12 inhibits anesthetic-induced desensitization of GABAA α3β3γ2 receptors with an IC50 of 0.2 μM. GABAA receptor modulator-12 can be used in the research of central nervous system disorders.
    GABAA receptor modulator-12
  • HY-W072274
    (S)-Desoxy-D2PM hydrochloride 188398-87-0 98%
    (S)-Desoxy-D2PM ((S)-2-Diphenylmethylpyrrolidine) hydrochloride is a neuroactive compound.
    (S)-Desoxy-D2PM hydrochloride
  • HY-W074537
    P7-2104 460346-02-5 99.77%
    P7-2104 is a blood-brain barrier-permeable, selective PDE7A inhibitor with an IC50 of 31 nM. P7-2104 shows selectivity for hERG channels and most CYP450 subtypes. P7-2104 can be used for PDE7-targeted PET neuroimaging studies and research related to neurodegenerative diseases, when labeled with 11C or 18F.
    P7-2104
  • HY-W083026
    (E)-CHBO4 126473-61-8
    (E)-CHBO4 is a MAO-B inhibitor, with an IC50 of 0.023 μM, and can be used for research on the study of Parkinson's disease.
    (E)-CHBO4
  • HY-W083062
    hMAO-B-IN-5 358343-63-2 99.66%
    hMAO-B-IN-5 (Compound B15) is a potent, selective and reversible human monoamine oxidase-B (hMAO-B) inhibitor with an IC50 of 120 nM and a Ki of 33 nM. hMAO-B-IN-5 can be used in the research of neurodegenerative diseases.
    hMAO-B-IN-5
Art. -Nr. Produktname / Synonyms Application Reactivity